SO-145 on skin microbiome for atopic dermatitis

Phase 1

Recruiting

• Conditions: atopic dermatitis; D003876

• Registration Number: JPRN-jRCTs041220073
• Lead Sponsor: Kondo Yasuto

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-10-14
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Among patients in their lower grades to 40s with mild atopic dermatitis
1. Patients who have received sufficient
explanation before participating in this study, and
who have obtained written consent at the
discretion of the patient or their guardian with sufficient understanding.
2. Staphylococcus epidermidis and Staphylococcus aureus carriers in patients with mild or mild eruption who have been diagnosed with atopic dermatitis based on the definition and diagnostic
criteria for atopic dermatitis.

Exclusion Criteria

1. Adrenal steroids Taking steroids, intensifying the platinum immunomodulatory drug
2. Basic sterilization Illness Slightly preventive bactericidal drug is taken internally
3. Patients who are recommended to use topical steroids on the face
4. Patients who originally use FSDG for soap
5. Patients, researchers, research coordinators

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of Staphylococcus epidermidis 12 weeks after the start of use

Secondary Outcome Measures

Name	Time	Method
1. Percentage of Staphylococcus epidermidis 4 and 12 weeks after the start of use and 4 weeks after<br>the end of use<br>2. Percentage of Staphylococcus aureus 4 and 12weeks after the start of use and 4 weeks after the end of use<br>(Measurement method: Sequence analysis of the bacterial flora on the cheeks of patients who have not used cosmetics for more than 7 hours after washing their face.)<br>3. Percentage of Staphylococcus aureus, TEWL, keratin water content, pH 4 and 12 weeks after the start of use and 4 weeks after the end of use<br>(Use the TEWL, keratin water content, and pH measurement results of the patient's cheeks 7 hours or<br>more after washing the face and without using cosmetics.)<br>4.Changes in serum TARC level, milk-specific IgE level, basophils, and amount of change in activation of effector cells 12 weeks after the start of use<br>5.Changes in bacterial flora diversity by skin bacterial flora sequence analysis 4 to 12 weeks after the start of use and 4 weeks after the end of use